Modifiers of Symptomatic Embolic Risk in Infective Endocarditis
Open accessAbstract
Objective To ascertain the impact of prior antiplatelet and statin therapy on symptomatic embolic events in [corrected] infective endocarditis (IE).Patients and methods We studied a retrospective cohort of adult patients with a diagnosis of IE who presented to Mayo Clinic (Rochester, MN) from January 1, 2003, to December 31, 2006. Patients were grouped into those who received treatment before infection or controls who did not receive treatment for both antiplatelet therapy and, separately, statin therapy. Because of the retrospective study design and thus the nonrandomized treatment groups, a propensity score approach was used to account for the confounding factors that may have influenced treatment allocation. Antiplatelet therapy included aspirin, dipyridamole, clopidogrel, ticlopidine or any combination of these agents. Statin therapy included atorvastatin, simvastatin, pravastatin, lovastatin, rosuvastatin, or fluvastatin. The primary end point was a symptomatic embolic event that occurred before or during hospitalization. Multivariable logistic regression was used to assess the propensity-adjusted effects of continuous daily therapy with antiplatelet and statin agents on risk of symptomatic emboli. Likewise, Cox proportional hazards regression was used to test for an independent association with 6-month mortality for each of the treatments.Results The study cohort comprised 283 patients with [corrected] IE. Twenty-eight patients (24.1%) who received prior continuous antiplatelet therapy developed a symptomatic embolic event compared with 66 (39.5%) who did not receive such treatment. After adjusting for propensity to treat, the effect of antiplatelet therapy on embolic risk was not statistically significant (odds ratio, 0.71; 95% confidence interval [CI], 0.37-1.36; P=.30). Only 14 patients (18.2%) who received prior continuous statin therapy developed a symptomatic embolic event compared with 80 (39.4%) of the 203 patients who did not. After adjusting for propensity to treat with statin therapy, the benefit attributable to statins was significant (odds ratio, 0.30; 95% CI, 0.14-0.62; P=.001). The 6-month mortality rate of the entire cohort was 28% (95% CI, 23%-34%). No significant difference was found in the propensity-adjusted rate of 6-month mortality between patients who had and had not undergone prior antiplatelet therapy (P=.91) or those who had and had not undergone prior statin therapy (P=.87).Conclusion The rate of symptomatic emboli associated with IE was reduced in patients who received continuous daily statin therapy before onset of IE. Despite fewer embolic events observed in patients who received antiplatelet agents, a significant association was not found after adjusting for propensity factors. A continued evaluation of these drugs and their potential impact on subsequent embolism among IE patients is warranted.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Retrospective, observational studies have examined the impact of long-term antiplatelet therapy before the onset of infective endocarditis on infection-related outcomes, and findings have been mixed.
“Retrospective, observational studies 290-296 have examined the impact, if any, of long-term antiplatelet therapy before the onset of IE on infection-related outcomes.Findings from these investigations have been mixed in terms of IE-related outcomes.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742 · see citing works
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · see citing works
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467 · see citing works
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638 · see citing works
Pedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098 · see citing works
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
Cines, D. B., Pollak, E. S., Buck, C. A., Loscalzo, J., Zimmerman, G. A., McEver, R. P., Pober, J. S., Wick, T. M., Konkle, B. A., Schwartz, B. S., et al. (1998) · PubMed · doi:10.1182/blood.v91.10.3527 · Cited by 2,244 · see citing works
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707 · see citing works
Self-citationStructural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644 · see citing works
Experience from a multicentre stroke register: a preliminary report.
Hatano, S. (1976) · PubMed · Cited by 1,522 · see citing works
Statins as a newly recognized type of immunomodulator.
Kwak, B., Mulhaupt, F., Myit, S., & Mach, F. (2000) · Nature Medicine · doi:10.1038/82219 · Cited by 1,383 · see citing works
Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase
Laufs, U., & Liao, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24266 · Cited by 1,035 · see citing works
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 920 · see citing works
Heiro, M., Nikoskelainen, J., Engblom, E., Kotilainen, E., Marttila, R., & Kotilainen, P. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.18.2781 · Cited by 415 · see citing works
Fibroblasts Can Be Genetically Modified to Produce Excitable Cells Capable of Electrical Coupling
Kizana, E., Ginn, S. L., Allen, D. G., Ross, D. L., & Alexander, I. E. (2005) · Circulation · doi:10.1161/01.cir.0000153812.64956.ef · Cited by 378 · see citing works
Complicated Left-Sided Native Valve Endocarditis in Adults
Hasbun, R., Vikram, H. R., Barakat, L., Buenconsejo, J., & Quagliarello, V. (2003) · JAMA · doi:10.1001/jama.289.15.1933 · Cited by 333 · see citing works
Sanfilippo, A. J., Picard, M. H., Newell, J. B., Rosas, E., Davidoff, R., Thomas, J. D., & Weyman, A. E. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90535-h · Cited by 328 · see citing works
Self-citationStatins Inhibit HIV-1 Infection by Down-regulating Rho Activity
del Real, G., Jiménez-Baranda, S., Mira, E., Lacalle, R. A., Lucas, P., Gómez‐Moutón, C., Alegret, M., Peña, J. M., Zapata, M. R., Álvarez‐Mon, M., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040061 · Cited by 294 · see citing works
A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis
Chan, K.-L., Dumesnil, J. G., Cujec, B., Sanfilippo, A. J., Jue, J., Turek, M. A., Robinson, T. I., & Moher, D. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00829-5 · Cited by 244 · see citing works
Statins for the Prevention and Treatment of Infections
Tleyjeh, I. M. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.286 · Cited by 236 · see citing works
Self-citationKupferwasser, L. I., Yeaman, M. R., Nast, C. C., Kupferwasser, D., Xiong, Y.-Q., Palma, M., Cheung, A. L., & Bayer, A. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16876 · Cited by 181 · see citing works
Kupferwasser, L. I., Yeaman, M. R., Shapiro, S. M., Nast, C. C., Sullam, P. M., Filler, S. G., & Bayer, A. S. (1999) · Circulation · doi:10.1161/01.cir.99.21.2791 · Cited by 169 · see citing works
Simvastatin Inhibits Inflammatory Properties of Staphylococcus aureus α-Toxin
Pruefer, D., Makowski, J., Schnell, M. G. O., Buerke, U., Dahm, M., Oelert, H., Sibelius, U., Grandel, U., Grimminger, F., Seeger, W., et al. (2002) · Circulation · doi:10.1161/01.cir.0000034048.38910.91 · Cited by 168 · see citing works
Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel
Serebruany, V. L., Midei, M. G., Malinin, A. I., Oshrine, B. R., Lowry, D. R., Sane, D. C., Tanguay, J., Steinhubl, S. R., Berger, P. B., O’Connor, C. M., et al. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.18.2051 · Cited by 156 · see citing works
Kupferwasser, L. I., Yeaman, M. R., Nast, C. C., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316876 · Cited by 152 · see citing works
Patterson, C., Stouffer, G. A., Madamanchi, N. R., et al. (2001) · Circulation Research · doi:10.1161/hh1001.091447 · Cited by 138 · see citing works
Impact of Prior Antiplatelet Therapy on Risk of Embolism in Infective Endocarditis
Anavekar, N. S., Tleyjeh, I. M., Anavekar, N. S., Mirzoyev, Z., Steckelberg, J. M., Haddad, C., Khandaker, M. H., Wilson, W. R., Chandrasekaran, K., & Baddour, L. M. (2007) · Clinical Infectious Diseases · doi:10.1086/513197 · Cited by 138 · see citing works
Self-citationCatron, D. M., Lange, Y., Borensztajn, J., Sylvester, M. D., Jones, B. D., & Haldar, K. (2004) · Infection and Immunity · doi:10.1128/iai.72.2.1036-1042.2004 · Cited by 111 · see citing works
Effect of Long-Term Aspirin Use on Embolic Events in Infective Endocarditis
Chan, K.-L., Tam, J., Dumesnil, J. G., Cujec, B., Sanfilippo, A. J., Jue, J., Turek, M., Robinson, T., & Williams, K. (2008) · Clinical Infectious Diseases · doi:10.1086/524021 · Cited by 95 · see citing works
Cerebrovascular accidents in infective endocarditis: role of anticoagulation
DELAHAYE, J. P., PONCET, P., Malquarti, V., Beaune, J., Garé, J. P., & Mann, J. M. (1990) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a059645 · Cited by 85 · see citing works
Sedlacek, M., Gemery, J. M., Cheung, A. L., Bayer, A. S., & Remillard, B. D. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.014 · Cited by 75 · see citing works
Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis
Nicolau, D. P., Freeman, C. D., Nightingale, C. H., Quintiliani, R., Coe, C. J., Maderazo, E. G., & Cooper, B. W. (1993) · Infection and Immunity · doi:10.1128/iai.61.4.1593-1595.1993 · Cited by 73 · see citing works
Thrombin Domains: Structure, Function and Interaction with Platelet Receptors
CRISTOFARO, R. D., & Candia, E. D. (2003) · Journal of Thrombosis and Thrombolysis · doi:10.1023/b:thro.0000011370.80989.7b · Cited by 69 · see citing works
Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis
Nicolau, D. P., Marangos, M. N., Nightingale, C. H., & Quintiliani, R. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1748 · Cited by 68 · see citing works
Serebruany, V. L., Miller, M. J., Pokov, A. N., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.058 · Cited by 67 · see citing works
Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis
Taha, T., Durrant, S., Mazeika, P. K., Nihoyannopoulos, P., & Oakley, C. M. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00971.x · Cited by 60 · see citing works
Undas, A., Brożek, J., & Musiał, J. (2002) · PubMed · Cited by 55 · see citing works
Nicolau, D. P., Tessier, P. R., & Nightingale, C. H. (1999) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(98)00092-2 · Cited by 54 · see citing works
Chronic antiplatelet therapy and mortality among patients with infective endocarditis
Pepin, J., Tremblay, V., Bechard, D., Rodier, F., Walker, C., Dufresne, D., Lafontaine, A., Li, N., Lacroix, C., & Lanthier, L. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02665.x · Cited by 42 · see citing works
Eisen, D. P., Corey, G. R., McBryde, E. S., Fowler, V. G., Miro, J. M., Cabell, C. H., Street, A. C., Paiva, M. G., Ionac, A., Tan, R.-S., et al. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.03.006 · Cited by 40 · see citing works
Schäfer, K., Kaiser, K., & Konstantinides, S. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-07-0415 · Cited by 34 · see citing works
Nicolau, D. P., Tessier, P. R., Nightingale, C. H., & Quintiliani, R. (1998) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(97)00056-3 · Cited by 26 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232 · see citing works
Self-citation
- Authors
- Anavekar, N. S., Schultz, J. C., De Sa, D. D. C., Thomas, J. M., Lahr, B. D., Tleyjeh, I. M., Steckelberg, J. M., Wilson, W. R., & Baddour, L. M.
- Affiliations
- Mayo Clinic (US)
- University of Minnesota (US)
- University of Pittsburgh (US)
- King Fahd Medical City (SA)
- Corresponding author
- Anavekar, Nandan S.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 86
- Issue
- 11
- Pages
- 1068-1074
- ISSN
- 0025-6196 (ISSN-L)
- PMC
- PMC3202997
- OpenAlex
- W1982455879
- Semantic Scholar
- c36aeb3db0d7689400896fe3af1780729d58ea79
- Cited by
- 31
- References
- 41
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 1 · 2016: 1 · 2015: 5 · 2014: 3 · 2013: 1 · 2012: 2
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-03-01)
- Open access
- bronze
- doi.org
- Locations
- Mayo Clinic Proceedings (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cardiovascular and Diving-Related Complications
- Keywords
- infective endocarditis, embolic events, antiplatelet therapy, statin therapy, aspirin, clopidogrel, ticlopidine, dipyridamole, 6-month mortality, propensity score adjustment
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Drug Therapy, Combination, Endocarditis, Female, Humans, Infant, Male, Middle Aged, Platelet Aggregation Inhibitors, Retrospective Studies, Thromboembolism, Logistic Models, Proportional Hazards Models, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult, Propensity Score
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
